Previous 10 | Next 10 |
ICAD (NASDAQ: ICAD ) initiated with Market Perform rating and $15 (163% upside) price target at JMP Securities. More news on: iCAD, Inc., National Health Investors, Inc., Sabra Health Care REIT, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
When you hear about penny stocks , oftentimes people will refer to technical indicators and momentum first. There are, of course, a catalyst that can be cited as a trigger for a short term move. But, in general, your average day trader looks at things like share volume and technical levels. We ...
Gainers: Protagonist Therapeutics (NASDAQ: PTGX ) +63% . More news on: Protagonist Therapeutics, Inc., Arbutus Biopharma Corporation, Kodiak Sciences Inc., Stocks on the move, Read more ...
Arbutus Biopharma Corporation (ABUS) Q3 2019 Earnings Conference Call November 6, 2019, 8:45 am ET Company Participants Pam Murphy - IR Consultant Bill Collier - President & CEO David Hastings - CFO Gaston Picchio - CDO Michael Sofia - CSO Conference Call Participants ...
Fluidigm (NASDAQ: FLDM ) -31% on Q3 results . More news on: Fluidigm Corporation, Plantronics, Inc., Amneal Pharmaceuticals, Inc., Stocks on the move, Read more ...
Arbutus Biopharma (NASDAQ: ABUS ): Q3 GAAP EPS of -$1.50 misses by $1.26 . Revenue of $3.1M (+93.8% Y/Y) misses by $2.18M . Shares +3.6% PM. Press Release More news on: Arbutus Biopharma Corporation, Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,
WARMINSTER, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its third quarter 2019 financial results and provides a corporate update. “We remain committed to our mission of ...
WARMINSTER, Pa., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its third quarter financial results, conference call and webcast for Wednesday, November 6, 2019. &...
The following slide deck was published by Arbutus Biopharma Corporation in conjunction with this Read more ...
Arbutus Biopharma ( ABUS -28% ) plummets to multi-year lows after discontinuing development of its AB-506 oral capsid inhibitor for the treatment of chronic hepatitis B after two normal healthy volunteers in a clinical trial developed cases of acute hepatitis. More news on: Arbutus Bio...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...